The Immunology Podcast

Dr. Kristin Anderson, a leading expert in tumor-infiltrating lymphocyte therapy, returns to discuss groundbreaking advances in immunotherapy. She highlights a successful phase two trial for metastatic melanoma that achieved a remarkable 31% response rate. The conversation also explores innovative strategies like the integration of PD-1 inhibitors and vaccine-prime approaches to enhance treatment effectiveness. Additionally, they touch on how nutrient availability and hormonal impacts affect T cell function, shedding light on new avenues for tackling autoimmune diseases.

Dive into the fascinating world of immunology as the hosts discuss cellular responses to microbial and parasitic infections, featuring innovative strategies and biobanking insights. Learn about the complexities of fetal-maternal tolerance and the role of glycan regulation during pregnancy. Discover groundbreaking monoclonal antibodies designed to tackle immune dysregulation. Enjoy lighthearted moments from the immunology conference, including a charming story about a llama and a motivational talk from an industry leader.

Highlights from the annual immunology meeting spark intriguing discussions around gut health, showcasing how environmental factors and IgA deficiency influence inflammation. Recent advances in T-cell therapies reveal innovative strategies for treating chronic inflammatory diseases. Fascinating developments in autoimmunity involve groundbreaking PD-1 agonist research and the use of machine learning for antibody optimization. Allergy research uncovers a critical link to hyper IgE phenotypes, enhancing our understanding of immune regulation.

Join Jason and Brenda at IMMUNOLOGY2024 as they discuss sessions on innate and innate-like cells and transplant immunology. Topics include hypothermia for lung damage protection, Siglec-E knockout in transplant rejection, jet lag strategies, NK cell development, inflammation, and risks in transplantation immunology.

Dr. Caleb Lareau discusses bioinformatics and immunology, focusing on herpesvirus reactivation in CAR T cells. The podcast also highlights the upcoming IMMUNOLOGY2024 event in Chicago and various research topics such as blocking lung injury in influenza and intestinal barrier defense.

Dr. Mitchell Kronenberg discusses his research on innate-like T cells and mucosal immunology, along with recent advancements in immunology science. Topics include immune system regeneration, antibody-drug conjugates for cancer, and the impact of Gasdermin in Pyroptosis. The episode also touches on AI in immunology research, targeting TRBC1 in T cell cancers, and exploring non-canonical T cells.

Dr. Scott Canna discusses auto- and hyperinflammatory diseases, IL-18's role, and adapting therapies. The podcast highlights research on microbial metabolites, T cell tolerance, and microbes in immunotherapy. Dr. Canna delves into HLH, IL-18 in autoinflammatory diseases, and challenges in diagnosis and treatment. The episode also covers vaccine innovations during the pandemic and scientific achievements.

Dr. Neelika Malavige talks about dengue burden, risk factors for severe disease. Also discusses COVID-19 vaccines, microbiome in colon cancer. Highlights growing research capabilities in Sri Lanka.

Dr. James Allison discusses breakthroughs in T-cell receptors for cancer immunotherapy, antibiotic development for resistance, and the impact of Tregs on metabolic function. The podcast also covers the evolution of immunotherapy, T cell persistence post-smoking cessation, and the intersection of music in the context of immunotherapy.

Dr. Akiko Iwasaki, Francisco Gomez-Rivera, and Dr. Jason Augustine talk about the upcoming IMMUNOLOGY2024 meeting. They discuss key sessions to attend, what they’re looking forward to, and offer advice for attendees. Other topics include streptococcus and gastric cancer, targeting senescent cells to prevent aging, and protein complexes and autoimmunity in mice. They also discuss the shrinking Y chromosome, collaboration in immunology, and insights in managing long COVID.